Safety fears trigger FDA hold for Regeneron pain med trial

The FDA has placed Regeneron's ($REGN) trial for an experimental pain medicine on hold, signaling that the entire drug class it belongs to could be in big trouble. The hold was announced after a patient in a different study involving a similar drug developed avascular necrosis, or bone tissue death triggered by a lack of blood supply.

REGN475/SAR164877 is an nerve growth inhibitor much like Pfizer's tanezumab, which was put on hold last summer after patients in a trial required joint replacements. A spokesman for Pfizer told Bloomberg the FDA is examining all anti-nerve growth drugs now in development.

"The FDA believes this additional case provides evidence to suggest" bone problems for the entire class, Regeneron said in a filing. The drug is partnered with Sanofi-Aventis.

- see Regeneron's SEC filing
- here's the Reuters story
- get the Bloomberg report

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.